About Rakuten Medical
Rakuten Medical is a biotechnology company developing investigational cancer therapies based on its proprietary Alluminox platform. This platform integrates a drug, a device, and other components to deliver photoimmunotherapy, a treatment that combines a light-activated dye with a targeting agent to selectively destroy cancer cells. The company's lead asset, ASP-1929, is an antibody-dye conjugate currently approved in Japan for treating unresectable locally advanced or recurrent head and neck cancer. Rakuten Medical is conducting global clinical trials to evaluate the safety and efficacy of its therapies in combination with other treatments. The company also offers an Expanded Access Program to provide investigational products to patients with serious or life-threatening diseases who lack other treatment options. Rakuten Medical operates in multiple countries and focuses on developing new cancer treatments based on its Alluminox™ platform.
Company details
Funding
Total raised
$900M
Last stage
Series F
Investors
Founders
Miguel Garcia-Guzman
Founded Aspyrian Therapeutics, Inc. in San Diego in 2010, which later became Rakuten Medical. Obtained exclusive license for NCI's photoimmunotherapy technology. Now serves as a Board Member.
Hiroshi "Mickey" Mikitani
Founder, Chairman and CEO of Rakuten Group, Inc. Joined and became a major backer of Aspyrian Therapeutics in 2013 and was appointed CEO of Rakuten Medical in 2018. Also a personal investor in the company.
LinkedInMinami Maeda
Joined Rakuten Medical in 2017; appointed CEO in 2026 following an executive leadership transition, succeeding Mickey Mikitani.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.